Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.

Proteomics. Clinical applications - 1 Sept 2020

Dwivedi Pankaj, Chutipongtanate Somchai, Muench David E, Azam Mohammad, Grimes Harry Leighton, Greis Kenneth D

Abstract excerpt

PURPOSE: To evaluate cellular protein changes in response to treatment with an approved drug, ibrutinib, in cells expressing normal or mutated granulocyte-colony stimulating factor receptor (G-CSFR). G-CSFR mutations are associated with some hematological malignancies. Previous studies show the efficacy of ibrutinib (a Bruton's tyrosine kinase inhibitor) in mutated G-CSFR leukemia models but do not address...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Leukemia, Myeloid

Share to Mutation

Share to Piperidines

Share to Proteomics

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 32319217
DOI: 10.1002/prca.201900144
PMCID: PMC7492401

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.PMID 32319217Read ↗

Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.Semantic proximity Read ↗

Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibSemantic proximity Read ↗

LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib ResistanceSemantic proximity Read ↗

Proteoform-level deconvolution reveals a broader spectrum of ibrutinib off-targetsSemantic proximity Read ↗

Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia.Semantic proximity Read ↗

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaSemantic proximity Read ↗

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.Semantic proximity Read ↗

Functional proteoform group deconvolution reveals a broader spectrum of ibrutinib off-targetsSemantic proximity Read ↗

RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.Semantic proximity Read ↗

Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.Semantic proximity Read ↗

Charting the molecular network of the drug target Bcr-AblSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.